Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C91385
http://purl.obolibrary.org/obo/NCIT_C91385
|
|---|---|
| Preferred Name | Belimumab |
| Definitions |
A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies. |
|---|---|
| prefLabel | Belimumab
|
| label | Belimumab
|
| PDQ_Closed_Trial_Search_ID | 680522
|
| code | C91385
|
| Has_Target | |
| prefixIRI | NCIT:C91385
|
| in_subset |
See more
See less
|
| Display_Name | Belimumab
|
| Preferred_Name | Belimumab
|
| FDA_UNII_Code | 73B0K5S26A
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Belimumab
|
| CAS_Registry | 356547-88-1
|
| NCI_Drug_Dictionary_ID | 680522
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 680522
|
| Accepted_Therapeutic_Use_For | Systemic Lupus Erythematosus
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C1723401
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |